Goldenwell Biotech (GWLL) Non-Current Debt (2023 - 2025)
Goldenwell Biotech (GWLL) has disclosed Non-Current Debt for 3 consecutive years, with $95588.0 as the latest value for Q1 2025.
- For the quarter ending Q1 2025, Non-Current Debt changed N/A year-over-year to $95588.0, compared with a TTM value of $95588.0 through Mar 2025, changed N/A, and an annual FY2024 reading of $95588.0, up 26.46% over the prior year.
- Non-Current Debt was $95588.0 for Q1 2025 at Goldenwell Biotech, roughly flat from $95588.0 in the prior quarter.
- Across five years, Non-Current Debt topped out at $95588.0 in Q4 2024 and bottomed at $75588.0 in Q4 2023.
- Average Non-Current Debt over 3 years is $88921.3, with a median of $95588.0 recorded in 2024.
- Peak annual rise in Non-Current Debt hit 26.46% in 2024, while the deepest fall reached 26.46% in 2024.
- Year by year, Non-Current Debt stood at $75588.0 in 2023, then increased by 26.46% to $95588.0 in 2024, then changed by 0.0% to $95588.0 in 2025.
- Business Quant data shows Non-Current Debt for GWLL at $95588.0 in Q1 2025, $95588.0 in Q4 2024, and $75588.0 in Q4 2023.